Morphology, Attenuation, Size, and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy

American Journal of Roentgenology

Volumn 194, Issue 6, 2010, Pages 1470-1478

  Smith, Andrew Dennis ^a   Shah, Shetal N ^a   Rini, Brian I ^b   Lieber, Michael L ^a   Remer, Erick M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Contrast enhanced CT; MASS criteria; Renal cell carcinoma; Response criteria; Tumor attenuation; Tumor morphology

Indexed keywords

SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; IOHEXOL; IOPROMIDE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME; TUMOR NECROSIS; DISEASE COURSE; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; IOHEXOL; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77953236472     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3456     Document Type: Article

References (12)

1. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
2. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764 (Pubitemid 46797958)
3. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759 (Pubitemid 46797957)
4. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24 (Pubitemid 46630489)
5. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14:1095-1097 (Pubitemid 350151265)
6. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR 2007; 189:360-370 (Pubitemid 47195921)
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134 (Pubitemid 46089673)
9. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: 123-131
10. Motzer RJ, Bacik J, Murphy BA, et al. Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296
11. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan- Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841
12. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-550